SecProbe.io

United States securities and exchange commission logo
March 20, 2024
Linda Wang
Chief Executive Officer
Akso Health Group
Room 8201-4-4(A), 2nd Floor, Qiantongyuan Building,
No. 44, Moscow Road, Qianwan Bonded Port Area
Qingdao Pilot Free Trade Zone, China (Shandong)
Re:Akso Health Group
Registration Statement on Form F-3
Filed February 23, 2024
File No. 333-277351
Dear Linda Wang:
            We have conducted a limited review of your registration statement and have the
following comment(s).
            Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe a comment applies to your facts and circumstances
or do not believe an amendment is appropriate, please tell us why in your response.
            After reviewing any amendment to your registration statement and the information you
provide in response to this letter, we may have additional comments.
Registration Statement on Form F-3
Part II
Item 9. Exhibits, page II-1
1.We note the asterisks included along with Exhibit 5.1 regarding your legal opinion as to
the legality of the securities being offered indicating that the legal opinion will be filed at
a later date and will be incorporated by reference. Please file a qualified legal opinion now
prior to effectiveness. Refer to Question 212.05 of our Securities Act Rules Compliance
and Disclosure Interpretations for guidance regarding qualified and unqualified legal
opinions and shelf takedowns.
2.We note that you are registering the offer and sale of debt securities and that you did not
file a Form T-1 as an exhibit. You must either file a Form T- 1 as an exhibit to the
registration statement to qualify the trustee thereunder or annotate the exhibit index to

 FirstName LastNameLinda Wang
 Comapany NameAkso Health Group
 March 20, 2024 Page 2
 FirstName LastName
Linda Wang
Akso Health Group
March 20, 2024
Page 2
indicate your intention to rely on Section 305(b)(2) of the Trust Indenture Act and include
the undertaking contained in Item 512(j) of Regulation S-K.
General
3.We note that you have outstanding comments related to your Form 20-F for the fiscal year
ended March 31, 2023.  Please note that all comments on your Form 20-F will need to be
fully resolved before we act on a request for acceleration of the effectiveness of the Form
F-3.
4.Please revise the filing, as applicable, to provide more specific and prominent disclosures
about the legal and operational risks associated with China-based companies. For
additional guidance, please see the Division of Corporation Finance’s Sample Letter to
China-Based Companies issued by the Staff in December 2021 (China-Based
Company Dear Issuer Letter). Additionally, please also revise the filing based upon the
China-based comments received on your Form 20-F for the fiscal year ended March 31,
2023.
            We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
            Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
            Please contact Jenna Hough at 202-551-3063 or Donald Field at 202-551-3680 with any
other questions.
Sincerely,
Division of Corporation Finance
Office of Trade & Services